Pasi A. Jänne

Top papers

• <i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, et al.·2004·Science
  ↗ 9,387
• Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

  Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, et al.·2010·New England Journal of Medicine
  ↗ 4,498
• <i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.·2007·Science
  ↗ 4,448OA
• The landscape of somatic copy-number alteration across human cancers

  Rameen Beroukhim, Craig H. Mermel, Dale Porter, et al.·2010·Nature
  ↗ 4,097OA
• <i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

  Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, et al.·2005·New England Journal of Medicine
  ↗ 3,927OA
• Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

  Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, et al.·2013·New England Journal of Medicine
  ↗ 3,396OA
• AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

  Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim, et al.·2015·New England Journal of Medicine
  ↗ 2,099OA
• Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

  Marcin Imieliński, Alice H. Berger, Peter S. Hammerman, et al.·2012·Cell
  ↗ 1,822OA
• <i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

  Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, et al.·2018·Cancer Discovery
  ↗ 1,583OA
• Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

  Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, et al.·2016·Nature Communications
  ↗ 1,551OA
• Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

  Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, et al.·2015·Nature Medicine
  ↗ 1,525OA
• Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

  David A. Eberhard, Bruce E. Johnson, Lukas C. Amler, et al.·2005·Journal of Clinical Oncology
  ↗ 1,483OA